Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 4/20 | 0.51 |
| ▸ | CTSS | P25774 | 3/20 | 0.51 |
| ▸ | SYK | P43405 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | KDM4A | O75164 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | ANPEP | P15144 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3640547 | 1.00 | CTSK (0.51) | CTSKCTSSSYKATMMALT1 | |
| SCHEMBL1624872 | 1.00 | CTSK (0.51) | CTSKCTSSSYKATMMALT1 | |
| SCHEMBL30209212 | 0.88 | SYK (0.42) | CTSKCTSSSYKATMMALT1 | |
| SCHEMBL19332332 | 0.87 | ANPEP (0.49) | CTSKCTSSSYKATMMEN1 | |
| SCHEMBL7834971 | 0.86 | CTSK (0.55) | CTSKCTSSSYKATMMALT1 | |
| SCHEMBL10290001 | 0.85 | CTSK (0.49) | CTSKCTSSSYKATMMALT1 | |
| SCHEMBL28763012 | 0.85 | CTSS (0.44) | CTSKCTSSSYKMALT1MEN1 | |
| SCHEMBL10317783 | 0.85 | MEN1 (0.50) | CTSKCTSSSYKMALT1IDO1 | |
| SCHEMBL10318441 | 0.85 | MEN1 (0.50) | CTSKCTSSSYKMALT1IDO1 | |
| SCHEMBL3658455 | 0.85 | GAA (0.47) | SYKIDO1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 151 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250346616-A1 | ROCK INHIBITORS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2025-11-13 | — | — | US | disclosed |
| US-20250340538-A1 | IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 | PERHA PHARMACEUTICALS (FR) | 2025-11-06 | — | — | US | disclosed |
| US-20250340539-A1 | IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1, AND/OR CLK4 | PERHA PHARMACEUTICALS (FR) | 2025-11-06 | — | — | US | disclosed |
| EP-4596051-A2 | HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION | Pharmacosmos Holding A/s (DK) | 2025-08-06 | — | — | EP | disclosed |
| US-12285431-B2 | Treatment of Rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors | PHARMACOSMOS HOLDING A/S (DK) | 2025-04-29 | — | — | US | disclosed |
| EP-2968291-B1 | HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION | PHARMACOSMOS HOLDING AS (DK) | 2025-04-16 | — | — | EP | disclosed |
| US-20240368136-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-11-07 | — | — | US | disclosed |
| WO-2024218632-A1 | ERK PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| EP-4422753-A1 | IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 | Perha Pharmaceuticals (FR) | 2024-09-04 | — | — | EP | disclosed |
| EP-4422747-A1 | IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 | Perha Pharmaceuticals (FR) | 2024-09-04 | — | — | EP | disclosed |
| WO-2012098065-A1 | PYRIDO PYRIMIDINES FOR USE AS DYRK1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-26 | — | — | WO | disclosed |
| WO-2012098070-A1 | QUINOLINE DYRK1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-26 | — | — | WO | disclosed |
| WO-2012098065-A1 | PYRIDO PYRIMIDINES FOR USE AS DYRK1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-26 | — | — | WO | disclosed |
| WO-2012098070-A1 | QUINOLINE DYRK1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-26 | — | — | WO | disclosed |
| US-20120184542-A1 | PYRIDO PYRIMIDINES | ANDERSON KEVIN (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120184542-A1 | PYRIDO PYRIMIDINES | ANDERSON KEVIN (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120184548-A1 | CARBOXYLIC ACID ARYL AMIDES | DOMINIQUE ROMYR (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120184548-A1 | CARBOXYLIC ACID ARYL AMIDES | DOMINIQUE ROMYR (US) | 2012-07-19 | — | — | US | disclosed |
| WO-2012061156-A1 | CDK INHIBITORS | TAVARES FRANCIS X (US) | 2012-05-10 | — | — | WO | disclosed |
| CN-101646427-A | Inhibitors of akt activity | SMITHKLINE BEECHAM CORP US | 2010-02-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12285431-B2 | Treatment of Rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors | RB1, CDK4, CDK6 | CTSK 2201/4885CTSS 3037/4885SYK 2925/4885 |
| US-20250346616-A1 | ROCK INHIBITORS AND USES THEREOF | ROCK1, ROCK2, RHOA | CTSK 1192/4885CTSS 2671/4885SYK 1211/4885 |
| US-20250340538-A1 | IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 | CLK1, CLK2, CLK3 | CTSK 533/4885CTSS 2514/4885SYK 2424/4885 |
| US-20240368136-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | CTSK 3049/4885CTSS 3952/4885SYK 596/4885 |
| US-20120184548-A1 | CARBOXYLIC ACID ARYL AMIDES | GOT1, PPARG, PPARA | CTSK 1003/4885CTSS 482/4885SYK 3356/4885 |
| US-20120184542-A1 | PYRIDO PYRIMIDINES | TYMS, TYMP, DPYD | CTSK 2557/4885CTSS 1322/4885SYK 2208/4885 |
| US-20250340539-A1 | IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1, AND/OR CLK4 | CLK1, CLK2, CLK3 | CTSK 422/4885CTSS 1774/4885SYK 1604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.